Detecting Insulin Resistance in Polycystic Ovary Syndrome: Purposes and Pitfalls

Richard Legro, V. Daniel Castracane, Robert P. Kauffman

Research output: Contribution to journalReview article

274 Citations (Scopus)

Abstract

Approximately 50% to 70% of all women with polycystic ovary syndrome (PCOS) have some degree of insulin resistance, and this hormone insensitivity probably contributes to the hyperandrogenism that is responsible for the signs and symptoms of PCOS. Although uncertainty exists, early detection and treatment of insulin resistance in this population could ultimately reduce the incidence or severity of diabetes mellitus, dyslipidemia, hypertension, and cardiovascular disease. Even if that proves to be the case, there are still several problems with our current approach to insulin sensitivity assessment in PCOS, including the apparent lack of consensus on what defines PCOS and "normal" insulin sensitivity, ethnic and genetic variability, the presence of other factors contributing to insulin resistance such as obesity, stress, and aging, and concern about whether simplified models of insulin sensitivity have the precision to predict treatment needs, responses, and future morbidity. Although the hyperinsulinemic-euglycemic clamp technique is the gold standard for measuring insulin sensitivity, it is too expensive, time-consuming, and labor-intensive to be of practical use in an office setting. Homeostatic measurements (fasting glucose/insulin ratio or homeostatic model assessment [HOMA]value) and minimal model tests (particularly the oral glucose tolerance test [OGTT]) represent the easiest office-based assessments of insulin resistance in the PCOS patient. The OGTT is probably the best simple, office-based method to assess women with PCOS because it provides information about both insulin resistance and glucose intolerance. The diagnosis of glucose intolerance holds greater prognostic and treatment implications. All obese women with PCOS should be screened for the presence of insulin resistance by looking for other stigmata of the insulin resistance syndrome such as hypertension, dyslipidemia, central obesity, and glucose intolerance.

Original languageEnglish (US)
Pages (from-to)141-154
Number of pages14
JournalObstetrical and Gynecological Survey
Volume59
Issue number2
DOIs
StatePublished - Feb 1 2004

Fingerprint

Polycystic Ovary Syndrome
Insulin Resistance
Glucose Intolerance
Glucose Tolerance Test
Dyslipidemias
Hypertension
Hyperandrogenism
Christianity
Glucose Clamp Technique
Abdominal Obesity
Signs and Symptoms
Uncertainty
Fasting
Consensus
Diabetes Mellitus
Cardiovascular Diseases
Therapeutics
Obesity
Hormones
Insulin

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Legro, Richard ; Castracane, V. Daniel ; Kauffman, Robert P. / Detecting Insulin Resistance in Polycystic Ovary Syndrome : Purposes and Pitfalls. In: Obstetrical and Gynecological Survey. 2004 ; Vol. 59, No. 2. pp. 141-154.
@article{81cc7d12073348aebb123989c192d072,
title = "Detecting Insulin Resistance in Polycystic Ovary Syndrome: Purposes and Pitfalls",
abstract = "Approximately 50{\%} to 70{\%} of all women with polycystic ovary syndrome (PCOS) have some degree of insulin resistance, and this hormone insensitivity probably contributes to the hyperandrogenism that is responsible for the signs and symptoms of PCOS. Although uncertainty exists, early detection and treatment of insulin resistance in this population could ultimately reduce the incidence or severity of diabetes mellitus, dyslipidemia, hypertension, and cardiovascular disease. Even if that proves to be the case, there are still several problems with our current approach to insulin sensitivity assessment in PCOS, including the apparent lack of consensus on what defines PCOS and {"}normal{"} insulin sensitivity, ethnic and genetic variability, the presence of other factors contributing to insulin resistance such as obesity, stress, and aging, and concern about whether simplified models of insulin sensitivity have the precision to predict treatment needs, responses, and future morbidity. Although the hyperinsulinemic-euglycemic clamp technique is the gold standard for measuring insulin sensitivity, it is too expensive, time-consuming, and labor-intensive to be of practical use in an office setting. Homeostatic measurements (fasting glucose/insulin ratio or homeostatic model assessment [HOMA]value) and minimal model tests (particularly the oral glucose tolerance test [OGTT]) represent the easiest office-based assessments of insulin resistance in the PCOS patient. The OGTT is probably the best simple, office-based method to assess women with PCOS because it provides information about both insulin resistance and glucose intolerance. The diagnosis of glucose intolerance holds greater prognostic and treatment implications. All obese women with PCOS should be screened for the presence of insulin resistance by looking for other stigmata of the insulin resistance syndrome such as hypertension, dyslipidemia, central obesity, and glucose intolerance.",
author = "Richard Legro and Castracane, {V. Daniel} and Kauffman, {Robert P.}",
year = "2004",
month = "2",
day = "1",
doi = "10.1097/01.OGX.0000109523.25076.E2",
language = "English (US)",
volume = "59",
pages = "141--154",
journal = "Obstetrical and Gynecological Survey",
issn = "0029-7828",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Detecting Insulin Resistance in Polycystic Ovary Syndrome : Purposes and Pitfalls. / Legro, Richard; Castracane, V. Daniel; Kauffman, Robert P.

In: Obstetrical and Gynecological Survey, Vol. 59, No. 2, 01.02.2004, p. 141-154.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Detecting Insulin Resistance in Polycystic Ovary Syndrome

T2 - Purposes and Pitfalls

AU - Legro, Richard

AU - Castracane, V. Daniel

AU - Kauffman, Robert P.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Approximately 50% to 70% of all women with polycystic ovary syndrome (PCOS) have some degree of insulin resistance, and this hormone insensitivity probably contributes to the hyperandrogenism that is responsible for the signs and symptoms of PCOS. Although uncertainty exists, early detection and treatment of insulin resistance in this population could ultimately reduce the incidence or severity of diabetes mellitus, dyslipidemia, hypertension, and cardiovascular disease. Even if that proves to be the case, there are still several problems with our current approach to insulin sensitivity assessment in PCOS, including the apparent lack of consensus on what defines PCOS and "normal" insulin sensitivity, ethnic and genetic variability, the presence of other factors contributing to insulin resistance such as obesity, stress, and aging, and concern about whether simplified models of insulin sensitivity have the precision to predict treatment needs, responses, and future morbidity. Although the hyperinsulinemic-euglycemic clamp technique is the gold standard for measuring insulin sensitivity, it is too expensive, time-consuming, and labor-intensive to be of practical use in an office setting. Homeostatic measurements (fasting glucose/insulin ratio or homeostatic model assessment [HOMA]value) and minimal model tests (particularly the oral glucose tolerance test [OGTT]) represent the easiest office-based assessments of insulin resistance in the PCOS patient. The OGTT is probably the best simple, office-based method to assess women with PCOS because it provides information about both insulin resistance and glucose intolerance. The diagnosis of glucose intolerance holds greater prognostic and treatment implications. All obese women with PCOS should be screened for the presence of insulin resistance by looking for other stigmata of the insulin resistance syndrome such as hypertension, dyslipidemia, central obesity, and glucose intolerance.

AB - Approximately 50% to 70% of all women with polycystic ovary syndrome (PCOS) have some degree of insulin resistance, and this hormone insensitivity probably contributes to the hyperandrogenism that is responsible for the signs and symptoms of PCOS. Although uncertainty exists, early detection and treatment of insulin resistance in this population could ultimately reduce the incidence or severity of diabetes mellitus, dyslipidemia, hypertension, and cardiovascular disease. Even if that proves to be the case, there are still several problems with our current approach to insulin sensitivity assessment in PCOS, including the apparent lack of consensus on what defines PCOS and "normal" insulin sensitivity, ethnic and genetic variability, the presence of other factors contributing to insulin resistance such as obesity, stress, and aging, and concern about whether simplified models of insulin sensitivity have the precision to predict treatment needs, responses, and future morbidity. Although the hyperinsulinemic-euglycemic clamp technique is the gold standard for measuring insulin sensitivity, it is too expensive, time-consuming, and labor-intensive to be of practical use in an office setting. Homeostatic measurements (fasting glucose/insulin ratio or homeostatic model assessment [HOMA]value) and minimal model tests (particularly the oral glucose tolerance test [OGTT]) represent the easiest office-based assessments of insulin resistance in the PCOS patient. The OGTT is probably the best simple, office-based method to assess women with PCOS because it provides information about both insulin resistance and glucose intolerance. The diagnosis of glucose intolerance holds greater prognostic and treatment implications. All obese women with PCOS should be screened for the presence of insulin resistance by looking for other stigmata of the insulin resistance syndrome such as hypertension, dyslipidemia, central obesity, and glucose intolerance.

UR - http://www.scopus.com/inward/record.url?scp=0942265414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0942265414&partnerID=8YFLogxK

U2 - 10.1097/01.OGX.0000109523.25076.E2

DO - 10.1097/01.OGX.0000109523.25076.E2

M3 - Review article

C2 - 14752302

AN - SCOPUS:0942265414

VL - 59

SP - 141

EP - 154

JO - Obstetrical and Gynecological Survey

JF - Obstetrical and Gynecological Survey

SN - 0029-7828

IS - 2

ER -